

BIOGEN IDEC INC.  
Form 8-K  
January 09, 2009

**Table of Contents**

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, DC 20549  
FORM 8-K  
CURRENT REPORT PURSUANT  
TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934  
Date of report (Date of earliest event reported): January 9, 2009  
Biogen Idec Inc.  
(Exact Name of Registrant as Specified in Its Charter)  
Delaware  
(State or Other Jurisdiction of Incorporation)**

**0-19311**  
(Commission File Number)

**33-0112644**  
(IRS Employer Identification No.)

**14 Cambridge Center, Cambridge, Massachusetts**  
(Address of Principal Executive Offices)

**02142**  
(Zip Code)

**(617) 679-2000**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))x
-

**TABLE OF CONTENTS**

Item 8.01. Other Events  
SIGNATURES

---

**Table of Contents**

**Item 8.01. Other Events.**

Biogen Idec Inc. (the Registrant ) will post on its web site after 4:30 p.m. (ET) each Friday information on confirmed cases of progressive multifocal leukoencephalopathy (PML) that have occurred in TYSABRI-treated patients since July 2006. This information can be found at [www.biogenidec.com/tpme](http://www.biogenidec.com/tpme). The first such posting today includes only previously disclosed cases of PML. The Registrant intends to post this information on its website through July 24, 2009, the third anniversary of the reintroduction of TYSABRI into the market.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: January 9, 2009

**Biogen Idec Inc.**

By: /s/ Robert A. Licht

Name: Robert A. Licht  
Title: Vice President and Assistant  
Secretary